RT Journal Article
SR Electronic
T1 The protection gap under a social health protection initiative in the COVID-19 pandemic: A case study from Khyber Pakhtunkhwa, Pakistan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.29.22282883
DO 10.1101/2022.11.29.22282883
A1 Khan, Sheraz Ahmad
A1 Cresswell, Kathrin
A1 Sheikh, Aziz
YR 2022
UL http://medrxiv.org/content/early/2022/12/12/2022.11.29.22282883.abstract
AB Background Sehat Sahulat Programme (SSP) is a Social Health Protection (SHP) initiative by the Government of Khyber Pakhtunkhwa (GoKP), covering inpatient services for 100% of the province’s population. In this paper, we describe SSP’s role in GoKP’s COVID-19 response and draw inferences for similar programmes in Pakistan.Methodology and methods We conceptualised SSP as an instrumental case study and collected three complementary data sources. First, we studied GoKP’s official documents to understand SSP’s benefits package. Then we undertook in-depth interviews and collected non-participant observations at the SSP policy and implementation levels. We recruited participants through direct (verbal and email) and indirect (invitation posters) methods.Use of maximum variation sampling enabled us to understand contrasting views from various stakeholders on SSP’s policy dimensions (i.e., coverage and financing), tensions between the policy directions (i.e., whether or not to cover COVID-19) and how policy decisions were made and implemented. We collected data from March 2021 to December 2021. Thematic analysis was conducted with the help of Nvivo12.Findings Throughout 2020, SSP did not cover COVID-19 treatment. The insurer and GoKP officials considered the pandemic a standard exclusion to insurance coverage. One SSP official said: “COVID-19 is not covered and not relevant to us”. GoKP had stopped non-emergency services at all hospitals. When routine services restarted, the insurer did not cover COVID-19 screening tests, which were mandatory prior to hospital admission.In 2021, GoKP engaged 10 private SSP hospitals for COVID-19 treatment. The SSP Reserve Fund, rather than insurance pooled money, was used. The Reserve Fund was originally meant to cover high-cost organ transplants. In 2021, SSP had 1,002 COVID-19-related admissions, which represented 0.2% of all hospital admissions (N=544,841).An advocacy group representative called the COVID-19 care under SSP “too little too late”. In contrast, SSP officials suggested their insurance database and funds flow mechanism could help GoKP in future health emergencies.Conclusion The commercially focused interpretation of SHP arrangements led to a protection gap in the context of COVID-19. SSP and similar programmes in other provinces of Pakistan should emphasise the notion of protection and not let commercial interests lead to protection gaps.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was made possible through a PhD funding from the Higher Education Commission of Pakistan. The funder did not influence the study design, data collection, analysis or reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We had ethics approval from the Ethics Committee at the University of Edinburgh and local ethics approval from the Khyber Medical University. We complied with the ethics regulations of informed consent, participants’ autonomy, confidentiality, and right to withdraw.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analysed during the current study are available from the corresponding author on reasonable request.